Open an account

Azenta

AZTA · NASDAQ

$35.73+$0.89 (+2.55%)TodayMarket closed ·
Prev close $34.84

About AZTA

Azenta, Inc. is a global provider of life sciences solutions, enabling organizations worldwide to bring impactful breakthroughs and therapies to market faster. The company is headquartered in Burlington, Massachusetts and currently employs 3,000 full-time employees. The firm provides a full suite of cold-chain sample management solutions and multiomics services across areas such as drug development, clinical research and advanced cell therapies for pharmaceutical, biotech, academic and healthcare institutions globally. The firm's segments include Sample Management Solutions and Multiomics. Its Sample Management Solutions segment offers end-to-end sample management products and services, including sample repository services and core products (automated stores, cryogenic systems, automated sample tube, consumables and instruments and controlled rate thawing devices). The firm's Multiomics segment includes its genomic services business, which advances research and development activities by providing gene sequencing, synthesis, editing and related services. The firm's brands include GENEWIZ, FluidX, Ziath, 4titude, Limfinity, Freezer Pro, and Barkey.

Employees
3,000
Headquarters
Burlington, Massachusetts
Listed
Feb 2, 1995
Sector
Health Care
Industry
Life Sciences Tools & Services
Website
azenta.com

AZTA key statistics

Market cap
1.57B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
1.27M
Volume
760.42K
Open price
$35.00
High today
$36.41
Low today
$34.51
52 Week high
$46.41
52 Week low
$15.93

Azenta (AZTA) at a glance

As of Oct 20, 2026, Azenta (AZTA) shares are priced at $35.73, giving the company a market cap of 1.57B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $34.51 and $36.41. The current price is 3.5% above the day's low and 1.9% below its high.

Volume so far is 760.42K shares, below the average of 1.27M shares a day.

Over the past year Azenta has ranged from $15.93 to $46.41, and now sits 65% of the way up that range.

Azenta met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q3 FY26 it reported $0.16 per share against an estimate of $0.1161.

The average analyst price target is $36.38, 1.8% above the current price, from 5 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

80%of 5 analyst ratings say Buy
  • Buy80.0%
  • Hold20.0%
  • Sell0.0%
Price target · 8 analystsAvg $36.38
Low
$33.33
Now
$35.73
High
$42.00

AZTA earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 38.3% on average.

  1. Q4 FY24: reported $0.18 per share against an estimate of $0.1048
  2. Q1 FY25: reported $0.08 per share against an estimate of $0.0583
  3. Q2 FY25: reported $0.05 per share against an estimate of $0.0714
  4. Q3 FY25: reported $0.19 per share against an estimate of $0.1395
  5. Q4 FY25: reported $0.21 per share against an estimate of $0.1933
  6. Q1 FY26: reported $0.09 per share against an estimate of $0.1405
  7. Q2 FY26: reported -$0.04 per share against an estimate of $0.126
  8. Q3 FY26: reported $0.16 per share against an estimate of $0.1161

AZTA news

  • Press releaseNewsfile

    ROSEN, LEADING INVESTOR COUNSEL, Encourages Azenta, Inc. Investors to Inquire About Securities Class Action Investigation - AZTA

  • Press releaseNewsfile

    ROSEN, NATIONALLY REGARDED INVESTOR RIGHTS COUNSEL, Encourages Azenta, Inc. Investors to Inquire About Securities Class Action Investigation - AZTA

  • Press releaseNewsfile

    ROSEN, TOP-RANKED TRIAL ATTORNEYS, Encourages Azenta, Inc. Investors to Inquire About Securities Class Action Investigation - AZTA

  • Press releaseNewsfile

    ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Azenta, Inc. Investors to Inquire About Securities Class Action Investigation - AZTA

  • Press releaseNewsfile

    ROSEN, SKILLED INVESTOR COUNSEL, Encourages Azenta, Inc. Investors to Inquire About Securities Class Action Investigation - AZTA

  • Press releaseNewsfile

    ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Azenta, Inc. Investors to Inquire About Securities Class Action Investigation - AZTA

  • Press releaseNewsfile

    ROSEN, A LEADING NATIONAL FIRM, Encourages Azenta, Inc. Investors to Inquire About Securities Class Action Investigation - AZTA

  • Press releaseNewsfile

    ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Azenta, Inc. Investors to Inquire About Securities Class Action Investigation - AZTA

Similar companies

Companies in the same industry as Azenta

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.